Acelrx announces $7.5 million registered direct offering of common stock and warrants to purchase common stock

Hayward, calif. , dec. 27, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx) (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 748,744 shares of its common stock, pre-funded warrants exercisable for an aggregate of 2,632,898 shares of common stock and common warrants exercisable for an aggregate of 4,227,052 shares of common stock.
ACRX Ratings Summary
ACRX Quant Ranking